Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

Clinical trial NCT01719380 · COMPLETED

Trial details

NCT number: NCT01719380
Sponsor: Pfizer
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Colorectal Cancer

Start date: 2012-11-23
Primary completion: 2015-10-31
Enrollment: 156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.